350 rub
Journal №10 for 2011 г.
Article in number:
IGF System and Breast Cancer
Keywords: IGF IGF receptors IGF binding proteins breast cancer antitumor target therapy
Authors:
O.I. Kostyleva, A.V. Maslyaev, O.M. Kuznetsova, A.A. Tuleuova, U.R. Mamedov, I.V. Tereshkina, T.T. Berezov
Abstract:
IGF system includes receptors and binding proteins, which form a complex regulated network of interactions, both among themselves and with other biological growth regulators and cell survival. Cellular effects of IGF are mediated by two types of specific IGF receptors, and insulin receptors, and hybrid receptor binds both insulin and IGF-1. IGF receptor 1 type (IGF-1R) is a glycosylated heterotetramer consisting of two extracellular α-subunits and two transmembrane β-subunits with the internal tyrosine kinase activity. Binding of IGF-1R with corresponding ligands leads to its oligomerization, autophosphorylation and activation of the internal tyrosine kinase. Then, IGF-1R tyrosine kinase phosphorylates the variety of cell substrates and signaling molecules involved in the regulation of apoptosis, the construction of the cytoskeleton and cell adhesion processes, as well as many other physiological processes in cells. IGF receptor type 2 (IGF-2R) is a cation-independent mannose 6-phosphate receptor and its role in the effects of IGF is still unclear. IGF-R1 is a mediator of the primary response of IGF, is expressed in all cell types except hepatocytes and T-lymphocytes, and serves as an important element of the normal growth and organism development. IGF signaling pathway is involved in the activation of the mitogen-activated protein kinases cascade and the signaling cascade. Key components of this system are the phosphatidylinositol 3-kinase (PI-3K) and protein kinase serine-threonine Akt. Activation of the mitogen-activated protein kinases cascade leads eventually to the inhibition of apoptosis and stimulation of cell proliferation. Circulating IGF binds with the high affinity binding proteins (IGFBP). Currently we know six different IGFBPs, as well as a family of homologous binding proteins, which have lower affinity for IGF-ligands. IGFBP modulate the bioavailability and activity of IGF in various ways. In the mammary gland IGF-1 is found mainly in the normal stromal cells, IGF-2 is also determined mainly in stromal cells, but can be detected in malignant breast epithelium. The high level of IGF-2 expression is associated with poor prognosis in breast cancer, and increased levels of IGF-1 in blood serum are an independent risk factor for breast cancer in premenopausal women. Since the action of IGF-1 and estrogen is correlated, we can assume that inhibition of both systems simultaneously may be more effective for the treatment of breast cancer than blocking each system separately. As a target for antitumor therapy could be perspective to try multiple action on IGF signaling pathway, including reduction and neutralization of IGF ligand, which downregulates IGF binding to receptors, and also developing of IGF independent antagonistic strategies.
Pages: 13-20
References
  1. Alberobello A.T., D'Esposito V., Marasco D. et al. Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death // J. Biol. Chem. 2010. V. 285. № 9. P. 6563-6572.
  2. Arnold J.T., Le H., McFann K.K., Blackman M.R. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells // Am. J. Physiol. Endocrinol. Metab. 2005. V. 288. № 3. P. 573-584.
  3. Baglietto L., English D.R., Hopper J.L. et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer // Cancer Epidemiol. Biomarkers Prev. 2007. V. 16. № 4. p. 763-768.
  4. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer // Curr. Pharm. Des. 2007. V. 13. № 7. P. 671-686.
  5. Bonanni B., Johansson H., Gandini S. et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women // Breast Cancer Res. Treat. 2001. V. 69. № 1. P. 21-27.
  6. Camirand A., Zakikhani M., Young F. et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells // Breast Cancer Res. 2005. V. 7. № 4. P. 570-579.
  7. Campbell C.I., Petrik J.J., Moorehead R.A. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis // Molecular Cancer. 2010. V. 9. № 1 P. 235-251.
  8. Campbell M.J., Woodside J.V., Secker-Walker J. et al. IGF status is altered by tamoxifen in patients with breast cancer // Mol. Pathol. 2001. V. 54. № 5. P. 307-310.
  9. Chen C., Freeman R., Voigt L.F. et al. Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor Receptor // Cancer Epidemiol. Biomarkers Prev. 2006. V. 15. P. 2461-2466.
  10. Chen C., Lewis S.K., Voigt L.F. et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein-3, and insulin // Cancer. 2004. V. 103. № 1. p. 76-84.
  11. Ciftci K., Su J., Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells // J. Pharm. Pharmacol. 2003. V. 55. № 8. P. 1135-1141.
  12. da Silva B.B., Moita D.S., Pires C.G. et al. Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene // Int. Semin. Surg. Oncol. 2007. V. 4. p. 18.
  13. Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies // Lancet Oncol. 2010. V. 11. № 6. P. 530-42.
  14. Eng-Wong J., Hursting S.D., Venzon D. et al. Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer // Cancer Epidemiol. Biomarkers Prev. 2003. V. 12. p. 1468-1473.
  15. Frasca F., Pandini G., Sciacca L. et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases // Arch. Physiol. Biochem. 2008. V. 114. № 1. P. 23-37.
  16. Freedland S.J., Aronson W.J. Examining the Relationship Between Obesity and Prostate Cancer // Rev. Urol. 2004. V. 6. № 2. p. 73-81.
  17. Fürstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer // Breast. 2006. V. 15. № 1. p. 64-68.
  18. Grimberg A. Mechanisms by which IGF-I may promote cancer // Cancer Biol. Ther. 2003. V. 2. № 6. p. 630-635.
  19. Gu F., Schumacher F.R., Canzian F. et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer // Cancer Epidemiol Biomarkers Prev. 2010. V. 19. № 11. P. 2877-2887.
  20. Guerreiro A.S., Boller D., Doepfner K.T., Arcaro A. IGF-IR: potential role in antitumor agents // Drug News Perspect. 2006. V. 19. № 5. P. 261-272.
  21. Haffner M.C., Petridou B., Peyrat J.Ph. et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer // BMC Cancer. 2007. V. 7. Р. 136.
  22. Hartog H., Wesseling J., Boezen H.M. et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future // Eur. J. Cancer. 2007. V. 43. № 13. p. 1895-1904.
  23. Holly J., Perks C. The role of insulin-like growth factor binding proteins // Neuroendocrinology. 2006. V. 83. № 3-4. P. 154-160.
  24. Ibrahim Y.H., Yee D. Insulin-like growth factor-I and breast cancer therapy // Clin. Cancer Res. 2005. V. 11. № 2(Pt 2). p. 944-950.
  25. Jameel J.K., Rao V.S., Cawkwell L., Drew P.J. Radioresistance in carcinoma of the breast // Breast. 2004. V. 13(6). P. 452-460.
  26. Johansson H., Baglietto L., Guerrierri-Gonzaga A. et al. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer // Breast Cancer Res. Treat. 2004. V. 88. № 1. p.63-73.
  27. Kahán Z., Gardi J., Nvári T. et al. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study // Int. J. Oncol. 2006. V. 29. № 1. p. 193-200.
  28. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer // Br. J. Cancer. 2007. V. 96 (Suppl.). P. 2-6.
  29. Laviola L., Natalicchio A., Giorgino F. The IGF-I signaling pathway // Curr. Pharm. Des. 2007. V. 13. № 7. P. 663-669.
  30. Levitt R.J., Buckley J., Blouin M.J. et al. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression // Biochem. Biophys. Res. Commun. 2004. V. 316. № 2. P. 421-428.
  31. Ling Y., Maile L.A., Clemmons D.R. Tyrosine phosphorylation of the ß3-subunit of the αVß3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor // Mol. Endocrinol. 2003. V. 17. P. 1824-1833.
  32. Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications // Oncology. 2002. V. 64. P. 317-332.
  33. Pavelić J., Matijević T., Knezević J. Biological & physiological aspects of action of insulin-like growth factor peptide family // Indian J. Med. Res. 2007. V. 125. № 4. p. 511-522.
  34. Paz K., Hadari Y.R. Targeted therapy of the insulin-like growth factor-1 receptor in cancer // Comb. Chem. High Throughput Screen. 2008. V. 11. № 1. p. 62-69.
  35. Pazaitou-Panayiotou K., Kelesidis T., Kelesidis I. et al. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer // Eur. J. Endocrinol. 2007. V. 156. № 2. p. 187-94.
  36. Platz E.A., Pollak M.N., Leitzmann M.F. et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era // Cancer Causes Control. 2005. V. 16. № 3. p. 255-262.
  37. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia // Nat. Rev. Cancer. 2004. V. 4. P. 505-518.
  38. Probst-Hensch N.M., Steiner J.H., Schraml P. et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity // Clin Cancer Res. 2010. V.16. № 3. P. 1025-1032.
  39. Prueitt R.L., Boersma B.J., Howe T.M. et al. Inflammation and IGF-I activate the Akt pathway in breast cancer // Int. J. Cancer. 2007. V. 120. № 4. p. 796-805.
  40. Rajski M., Zanetti-Dällenbach R., Vogel B. et al. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients // BMC Med. 2010. V. 5. № 8. № 1. P. 18-36.
  41. Ren Z., Shin A., Cai Q. et al. IGFBP3 mRNA expression in benign and malignant breast tumors // Breast Cancer Res. 2007. V. 9. № 1. p. 2-11.
  42. Renehan A.G., Zwahlen M., Minder C. et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis // Lancet. 2004. V. 363. № 9418. p. 1346-1353.
  43. Rollison D.E., Newshaffer C.J., Tao Y. et al. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer // Int. J. Cancer. 2006. V. 118. № 5. p. 1279-1284.
  44. Samani A.A., Yakar S., LeRoith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights // Endocr. Rev. 2007. V. 28. № 1. P. 20-47.
  45. Schernhammer E.S., Holly J.M, Hunter D.J. et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II // Endocr. Relat. Cancer. 2006. V. 13. № 2. p. 583-592.
  46. Singer C.F., Mogg M., Koestler W. et al. Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions // Clin. Cancer Res. 2004. V. 10. p. 4003-4009.
  47. Sisci D., Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer // Curr. Pharm. Des. 2007. V. 13. № 7. P. 705-717.
  48. Smith J., Axelrod D., Singh B., Kleinberg D. Prevention of breast cancer: the case for studying inhibition of IGF-1 actions // Ann. Oncol. 2011. Suppl. 1. P. 50-52.
  49. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy // Proc. Natl. Acad. Sci. USA. 2010. V. 107. № 24. P. 10791-10798.
  50. Varela-Nieto I., Hartl M., Gorospe I., Leon Y. Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformation // Curr. Pharm. Des. 2007. V. 13. № 7. P. 687-703.
  51. Vestey S.B., Perks C.M., Sen Ch. et al. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome // Breast Cancer Res. 2005. V. 7. № 1. p. 119-129.
  52. Weiss J.M., Huang W.Y., Rinaldi S. et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial // Int. J. Cancer. 2007. V. 121. № 10. P. 2267-2273.
  53. Werner H. and Bruchim I. Basic and clinical significance of IGF-I-induced signatures in cancer // BMC Med. 2010. V. 8. № 1. P. 2-18.
  54. Werner H., Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action // Trends Endocrinol. Metab. 2006. V. 17. № 6. p. 236-242.
  55. Yakar S., Leroith D., Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models// Cytokine Growth Factor Rev. 2005. V. 16. P. 407-420.
  56. Zhang S., Li X., Burghardt R. et al. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells // J. Mol. Endocrinol. 2005. V. 35. № 3. P. 433-447.
  57. Zhang X., Yee D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer // Breast Cancer Res. 2000. V. 2. № 3. p. 170-175.